Red Oak worked with a Company to develop plans for a business based on the Company’s patented process for using buckwheat derivatives in treating Type II diabetes.  The U.S. has over 21 million diabetics, with diabetes taking an increasing proportion of healthcare budgets.

Technical data and patents licensed from Cornell University, University of Manitoba and other sources were useful in planning human clinical trials.  Nutraceuticals from buckwheat are clearly in line with the growing consumer interest and acceptance of food to help promote good health.

Red Oak assisted the Company in locating pilot-plant scale production of the product at concentration levels suitable for use in human clinical trials, identifying sources to conduct the clinical trials, and locating a commercial scale production facility.